Drug companies, health technology assessment bodies, ethicists and patient groups are among the raft of stakeholders that can now have their say on the multi-stakeholder platform (MSP) that EU regulators want to set up this year to enable discussions on improving Europe’s clinical trials landscape.
The MSP’s establishment is described in a concept paper that the European Medicines Agency, the EU’s Heads of Medicines Agencies...